1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline has been researched along with ubiquinone in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlson, EC; Ebadi, M; Shavali, S; Swinscoe, JC | 1 |
1 other study(ies) available for 1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline and ubiquinone
| Article | Year |
|---|---|
1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells.
Topics: Adenosine Triphosphate; alpha-Synuclein; Antioxidants; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Coenzymes; Cysteine Proteinase Inhibitors; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation; Glutathione; Humans; Immunohistochemistry; Microscopy, Electron; Nerve Tissue Proteins; Neuroblastoma; Neuroprotective Agents; Oligopeptides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selegiline; Synucleins; Tetrahydroisoquinolines; Time Factors; Ubiquinone | 2004 |